Merck antiviral molnupiravir for covid-19 has showed positive results. Thus it has continued to pay off through supply deals. J&J has inked a deal of $1 Bn sale order deal. The company will supply 1.6 million courses worth $1.2 billion.
Japan inked the deal with Merck & Co following receiving approval for the medicine from Pharmaceuticals and Medical Devices Agency of Japan. Earlier in October, the medicine which was taken 800 mg twice daily showed reduced risk of hospitalization or fatality from covid-19. The percentage of death and hospitalization was reduced by 50% in adult patients.
Meanwhile the competitive rival of Merck, Pfizer has revealed that its Paxlovid medicine has showed positive results. It has revealed that Paxlovid can reduce hospitalization and death upto 89%. As a result, due to the positive data, the company has sought emergency authorization from FDA for Paxlovid to bring it in the US and other markets across the world.